Advertisement Lilly reports positive results from Phase III trial of ixekizumab to treat psoriatic arthritis - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Lilly reports positive results from Phase III trial of ixekizumab to treat psoriatic arthritis

Eli Lilly and Company has announced that a Phase III trial (SPIRIT-P1) of its investigational medicine, ixekizumab, met the primary endpoint in the treatment of patients with psoriatic arthritis (PsA), a progressive, chronic and destructive disease.

According to the data, ixekizumab was statistically superior to placebo in the treatment of patients with active PsA, as showed by the proportion of patients achieving an ACR 20 response.

ACR 20 is a standard assessment that represents a 20% reduction in disease signs and symptoms as defined by the American College of Rheumatology response criteria.

In the 24-week trial, patients who were naïve to biologic disease-modifying antirheumatic drugs (bDMARD) were treated with one of two different ixekizumab dosing regimens or placebo.

In both dosing regimens, ixekizumab-treated patients showed significant improvements versus placebo in signs and symptoms of active PsA.

PsA can cause swelling, stiffness and pain in and around the joints, nail changes and impaired physical function.

Lilly Bio-Medicines Product Development senior vice-president Anthony Ware said: "Psoriatic arthritis is a debilitating disease associated with progressive joint damage and skin involvement, and also has a significant impact on a person’s quality of life.

"These results strengthen our belief that ixekizumab may have the potential to help people confronting this challenging disease."